Æ÷½ºÅÍ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2014³â 9¿ù 26ÀÏ(±Ý) ~ 2014³â 9¿ù 27ÀÏ(Åä)
- Àå¼Ò : EXHIBITION HALL B[1F] |
(07:00~07:00) |
ÁÂÀå : |
86-GO107:00~07:00 |
°¿ì´ë Àü³²´ëÇб³º´¿ø »êºÎÀΰú |
Diagnostic accuracy of human papillomavirus genotyping |
87-GO207:00~07:00 |
°Á¤¹è ÇѸ²ÀÇ´ë µ¿Åº¼º½Éº´¿ø »êºÎÀΰú |
Malignant Perivascular Epithelioid Cell Tumor(PEComa) of the Uterus with Lung Metastasis |
88-GO307:00~07:00 |
±âÀº¿µ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
A clinicopathological review of pulmonary metastasis from uterine cervical cancer. |
89-GO407:00~07:00 |
±è¿ÏÁÖ °æ»ó´ëÇб³º´¿ø »êºÎÀΰú |
An unusual presentation of a rectal duplication cyst accompanying large uterine myoma(case report) |
90-GO507:00~07:00 |
±è¿ë¼® ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
Effects of hemostatic sealant in preservation of ovarian reserve during laparoscopic ovarian cystectomy |
91-GO607:00~07:00 |
±èÅÂÈÆ ¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú |
Pretreatment Neutrophil:Lymphocyte Ratio and Platelet:Lymphocyte Ratio as a Prognostic
factor in locally advanced cervical cancer |
92-GO707:00~07:00 |
±èÈñ½Â ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Conventional Versus Nerve-sparing Radical Surgery for Cervical Cancer: A Meta-analysis Including 2,280 Women With Cervical Cancer From 21 Comparative Studies |
93-GO807:00~07:00 |
±èÈñ½Â ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Success factors of laparoscopic nerve-sparing radical hysterectomy for preserving bladder function in patients with cervical cancer: a protocol-based prospective cohort study |
94-GO907:00~07:00 |
·ùÁöÀ± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
The role of SK1 (sphingosine kinase 1) in epithelial ovarian cancer |
95-GO1007:00~07:00 |
·ùÇö°æ Àü³²´ëÇб³º´¿ø »êºÎÀΰú |
The prognostic value of squamous cell carcinoma antigen in the prediction of tumor recurrence in cervical carcinoma patients with various clinical characteristics. |
96-GO1107:00~07:00 |
¹Ú¿¹±Ô ´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú |
Case report: Deep vulva malignant melanoma in premenopausal woman |
97-GO1207:00~07:00 |
¹Ú¿¹±Ô ´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú |
Case report: Pure-type Large cell Neuroendocrine carcinoma of the ovary in premenopausal woman |
98-GO1307:00~07:00 |
¹ÚÁ¤¹Î ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
The Effects of Body Mass Index on Survival Outcomes in Patients With Cervical Carcinoma (IB1 to IVA) |
99-GO1407:00~07:00 |
¹ÚÁØ½Ä ¼øõÇâÀÇ´ë ºÎõº´¿ø »êºÎÀΰú |
Paratubal Serous Bordeline Tumor: a Case Report |
100-GO1507:00~07:00 |
¹ÚÁØ½Ä ¼øõÇâÀÇ´ë ºÎõº´¿ø »êºÎÀΰú |
Benign Cystic Mesothelioma which Can Mimic Gynecologic Malignancies: a Case Report |
101-GO1607:00~07:00 |
¹Úö¹Î Á¦ÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Primary omental torsion diagnosed during hysterectomy |
102-GO1707:00~07:00 |
¹ÚÈ¿°æ ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Patterns of recurrence and survival after abdominal versus laparoscopic/robotic radical
hysterectomy in patients with early cervical cancer |
103-GO1807:00~07:00 |
¹èÈ¿¼÷ °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Atypical endometriosis: Morphologic, immunohistochemical and molecular changes |
104-GO1907:00~07:00 |
¹èÈ¿¼÷ °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Sexual function and Treatment Modalities in Cervical Cancer Patients: Systematic Review
and Meta-analysis |
105-GO2007:00~07:00 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Survival analysis of Revised 2013 FIGO Staging Classification of Epithelial Ovarian Cancer and Comparison with Previous FIGO Staging Classification |
106-GO2107:00~07:00 |
º¯½Â¿ø °¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú |
Efficacy of preemptive port site local analgesia for wound pain after gynecologic laparoendoscopic single-site surgery |
107-GO2207:00~07:00 |
º¯½Â¿ø °¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú |
Vaginal cuff closure with unidirectional barbed suture during total laparoscopic hysterectomy is a safe and feasible procedure. |
108-GO2307:00~07:00 |
º¯Á¤¹Ì ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú |
The importance of diagnosis of endometrial cancer arising from atypical complex hyperplasia |
109-GO2407:00~07:00 |
¼µ¿ÈÆ ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Critical points for inexperienced surgeons to successfully perform laparoscopic radical hysterectomy versus abdominal radical hysterectomy in early-stage cervical cancer: matched-case comparisons |
110-GO2507:00~07:00 |
¼Á¤¿ø ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Dose diabetes medication reduce recurrence of endometrial cancer ? |
111-GO2607:00~07:00 |
¼®ÇýÁø ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Robot-assisted radical hysterectomy combined with vaginal approach for the patients with bulky cervical cancer : feasibility and operative results |
112-GO2707:00~07:00 |
¼ÕÁÖÇõ ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Prediction of lymph node metastasis in patients with apparent early endometrial cancer |
113-GO2807:00~07:00 |
¼Û¹ÎÁ¾ °¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø »êºÎÀΰú |
Single port laparoscopic transumbilical extraperitoneal paraaortic lympadenectomy for surgical staging in locally advanced cervical cancer |
114-GO2907:00~07:00 |
¼Û¹ÎÁ¾ °¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø »êºÎÀΰú |
Anti-cancer effect of bee venom via increase of death receptor expression and inactivation of NF-B in human cervical cancer |
115-GO3007:00~07:00 |
¼ÛÀº¼· ÀÎÇÏ´ëÇб³º´¿ø »êºÎÀΰú |
he Clinical Impact Of Human Papilloma Virus On the Patients With ASCUS/LSIL
|
116-GO3107:00~07:00 |
À±°¡¿µ ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Simultaneous Borderline mucinous tumor, Mature cystic teratoma and Endometriosis in the Same Ovary
|
117-GO3207:00~07:00 |
À±¾Ö¶ó ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Therapeutic Targeting of C-MET in Ovarian Clear-Cell Carcinoma |
118-GO3307:00~07:00 |
ÀÌ´ë¿ì °¡Å縯ÀÇ´ë ºÎõ¼º¸ðº´¿ø »êºÎÀΰú |
Premature hepatic metastasis of ovarian yolk sac tumor
|
119-GO3407:00~07:00 |
ÀÌ¹Î¾Æ ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú |
Micronutrients and Clearance of Human Papillomavirus: a Meta-Analysis |
120-GO3507:00~07:00 |
À̹æÇö ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Onset of chemotherapy-induced severe neutropenia in patient with ovarian cancer |
121-GO3607:00~07:00 |
À̹æÇö ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
The effect of human papillomavirus genotyping on triage of atypical squamous cells of undetermined significance |
122-GO3707:00~07:00 |
ÀÌ»óÈÆ ¿ï»ê´ëÇб³º´¿ø »êºÎÀΰú |
Ovarian Microcystic Stromal Tumor (MCST): a Novel Extracolonic Tumor in Familial Adenomatous Polyposis |
123-GO3807:00~07:00 |
ÀÌ½Â¹Ì ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Long-term follow-up study of adult-type ovarian granulosa cell tumor |
124-GO3907:00~07:00 |
À̽ÅÈ ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Prognostic significance of treatment-induced pathologic remission and adjuvant chemotherapy after interval cytoreduction following neoadjuvant chemotherapy in epithelial ovarian cancer |
125-GO4007:00~07:00 |
ÀÌ¿¬¾Æ Ãæ³²´ëÇб³º´¿ø »êºÎÀΰú |
a case of Liposarcoma like subserosal myoma with endometrial carcinoma in uterus |
126-GO4107:00~07:00 |
ÀÌ¿µÀç Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú |
³¼Ò ±âÇüÁ¾ÀÇ ¾Ç¼ºµµ ¹× Á¾¾ç Å©±â¿Í ¼ö¼ú Àü CA19-9ÀÇ »ó°ü°ü°è |
127-GO4207:00~07:00 |
ÀÌ¿ÏÈ£ Àü³²´ëÇб³º´¿ø »êºÎÀΰú |
Is vaginal cytology and CA-125 measurement useful to detect recurrent endometrial cancer in postoperative patients ? |
128-GO4307:00~07:00 |
ÀÌ¿ø¹« ÇѾç´ëÇб³º´¿ø »êºÎÀΰú |
The prognostic significance of steroid sulfatase in patients with endometrial cancer
|
129-GO4407:00~07:00 |
ÀÌÀ¯°æ
|
Phosphorylation of AKT and hTERT expression are associated with prognosis of epithelial ovarian carcinomas |
130-GO4507:00~07:00 |
ÀÌÀ±Èñ Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
The prognosis of hydronephrosis after treatment in gynecologic malignancy. |
131-GO4607:00~07:00 |
ÀÌÀοÁ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Clinicopathologic characteristics of ovarian Sertoli-Leydig cell tumors. |
132-GO4707:00~07:00 |
ÀÌÁöÇý °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
T-cell immune response to human papillomavirus 16 for predicting the cytological progress |
133-GO4807:00~07:00 |
ÀÌÇý³² Â÷ÀÇ°úÇдëÇб³ °³²Â÷º´¿ø »êºÎÀΰú |
ÀÚ±ÃÆòÈ°±ÙÀ°Á¾ ¹× Àڱ󻸷±âÁúÀ°Á¾ÀÇ ´ÜÀϱⰣ¿¡¼ÀÇ 14³â°£ÀÇ °æÇè |
134-GO4907:00~07:00 |
ÀåÇÏ±Õ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Retrospective analysis of 63 cases with endometrial stromal sarcoma, leiomyosarcoma and carcinosarcoma in CMC, Korea, 1990-2013. |
135-GO5007:00~07:00 |
ÀüÇý°æ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
High-throughput molecule screen in clear cell carcinoma |
136-GO5107:00~07:00 |
Á¤¾ð¼® ÇѾç´ëÇб³º´¿ø »êºÎÀΰú |
Laparoscopic para-aortic lymphadenectomy up to the renal vein level
: Surgical approach and outcomes from single surgical team 10-year experience
|
137-GO5207:00~07:00 |
Á¤¿¬¼ö ±¹¹Î°Ç°º¸Çè°ø´Ü Àϻ꺴¿ø »êºÎÀΰú |
ANTIPROLIFERATIVE AND APOPTOTIC ACTIVITY OF MÜLLERIAN INHIBITING SUBSTANCE (MIS) AND CALCITRIOL CO-TREATMENT OF OVARIAN CANCER CELL LINES |
138-GO5307:00~07:00 |
Á¤¿µ½Å ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Total vaginal necrosis after radiation for recurrent cervical cancer : a case report |
139-GO5407:00~07:00 |
Á¤À±Áö °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Müllerian inhibiting substance functions as tumor suppressor by regulating multiple components of cancer-related pathways in human uterine endometrial cancer |
140-GO5507:00~07:00 |
Á¤Çý¿ø °è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú |
The Treatment of Pazopanib on Vulvar Epithelioid Sarcoma: A Case Report and Review of Literature |
141-GO5607:00~07:00 |
Á¶¿µÀç ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Anti-cancer effect of Linalool in Epithelial Ovarian Cancer |
142-GO5707:00~07:00 |
Á¶¿µÀç ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Patient-derived xenograft models identify HER2 as a therapeutic target in HER2-amplified cervical cancer |
143-GO5807:00~07:00 |
Á¶Àººñ ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú |
Metastatic choriocarcinoma as initial presentation of small bowel perforation in absence of primary uterine lesion: A case report |
144-GO5907:00~07:00 |
Á¶Çý¿¬ ÇѸ²ÀÇ´ë µ¿Åº¼º½Éº´¿ø »êºÎÀΰú |
Comparison of HE4, CA125, and risk of ovarian malignancy algorithm (ROMA) for the differential diagnosis of ovarian cancer from benign pelvic mass |
145-GO6007:00~07:00 |
Â÷ÁÖÀº ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú |
Carcinoid tumor arising in ovarian mature cystic teratoma and coexisting mature cystic teratoma of omentum, peritoneum and ovary : A Case Report |
146-GO6107:00~07:00 |
ÃÖ¿¹Áø ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø »êºÎÀΰú |
Choriocarcinomatosis dedifferentiation from adenocarcinoma of the uterine cervix: A case report |
147-GO6207:00~07:00 |
ÃÖÀ±Áø °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Parents¡¯ knowledge and attitude towards HPV vaccination in Korea :Implications for Health communications |
148-GO6307:00~07:00 |
ÃÖÀοµ °æ»ó´ëÇб³º´¿ø »êºÎÀΰú |
Adenoid cystic carcinoma of Bartholin¡¯s gland in menopause women |
149-GO6407:00~07:00 |
ÃÖÇýÁø °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
Clinical utility of dual-phase 18F-FDG PET/CT for predicting the outcome in patients with cervical carcinoma |
150-GO6507:00~07:00 |
Çѽ¼ö Áß¾Ó´ëÇб³º´¿ø »êºÎÀΰú |
The value of preoperative platelet count in the prediction of prognosis in patients with endometrial cancer |
151-GO6607:00~07:00 |
ÇÑ¿ì¼® ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Prognostic significance of serum CA-125 levels rising within the normal range in patients with epithelial ovarian cancers, and a complete clinical response |
152-GO6707:00~07:00 |
Thi My Hien Nguyen Áß¾Ó´ëÇб³º´¿ø »êºÎÀΰú |
ITM2A, down-regulated in serous ovarian cancer patients has anti-tumoral activity of ovarian cancer cells by inducing G2/M cell cycle arrest. |
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2014³â 9¿ù 26ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F] |
GO1-GO4 (08:20~09:00) |
ÁÂÀå : ·ù±â¼º(°¡Å縯ÀÇ´ë) |
GO108:20~08:30 |
³²ÀºÁö ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Pancreatic adenocarcinoma up-regulated factor (PAUF) expression in ovarian mucinous adenocarcinoma associated with a poor prognosis |
GO208:30~08:40 |
¾ç¼±¿µ °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
ASC-US and LSIL triage in Korean women: Revisiting the 2012 ASCCP screening guidelines |
GO308:40~08:50 |
±èÁ¤Àº °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
Prediction model for 30-day morbidity after gynecological malignancy surgery |
GO408:50~09:00 |
ÇãÀºÁø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
The impact of the interval from surgery to initiation of chemotherapy (ISC) on survival in advanced epithelial ovarian cancer |
GO5-GO8 (09:00~09:40) |
ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë) |
GO509:00~09:10 |
¹èÈ¿¼÷ ±¹¸³¾Ï¼¾ÅÍ |
Predictive factor and risk group analysis for the local recurrence/persistent disease in
cervical cancer patients who underwent primary concurrent chemoradiotherapy (CCRT) |
GO609:10~09:20 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Laparoscopic surgical management of localized recurrent ovarin cancer |
GO709:20~09:30 |
ÀÓ¸íö ±¹¸³¾Ï¼¾ÅÍ |
A simple new technique of diaphragmatic peritonectomy: hand-pushing down with anchoring both ends |
GO809:30~09:40 |
ÀÌÁ¤¿ø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Anti-angiogenic Effect of Itraconazole in Epithelial Ovarian Cancer |
GO9-GO12 (09:40~10:20) |
ÁÂÀå : ³²°èÇö(¼øõÇâÀÇ´ë) |
GO909:40~09:50 |
¼µ¿ÈÆ ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Survival impact of surgical spillage in stage I clear cell carcinoma of ovary: Korean multicenter study. |
GO1009:50~10:00 |
Á¤Çʽ ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Poor prognosis after conservative surgery in stage I mucinous epithelial ovarian cancer |
GO1110:00~10:10 |
ÀÌÁ¤À± ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
A low-risk group for parametrial involvement is accurately identified by criteria used in ongoing studies and new criteria using MRI in microscopic stage IB1 cervical cancer |
GO1210:10~10:20 |
ÀÓ¸íö ±¹¸³¾Ï¼¾ÅÍ |
Colon cancer as a second primary cancer after endometrial cancer based on shared etiology: a proof of concept study |
GO13-GO16 (11:00~11:40) |
ÁÂÀå : ¹®Çý¼º(ÀÌÈÀÇ´ë) |
GO1311:00~11:10 |
±â°æµµ °µ¿°æÈñ´ëÇб³º´¿ø »êºÎÀΰú |
XAF1 is activated by TNF¥á and mediated TNF¥á-induced apoptosis in ovarian cancer cells |
GO1411:10~11:20 |
ÀÓ°¡¿ø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Long non-coding RNA HOXA11as is associated with survival in advanced epithelial ovarian cancer |
GO1511:20~11:30 |
±¸À¯Áø °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
Discordance of histopathologic diagnosis between colposcopy-guided biopsy and conization in high-grade cervical intraepithelial lesions |
GO1611:30~11:40 |
Á¤Çʽ ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Diagnostic value of combined 18F-FDG positron emission tomography/computed tomography in recurrent epithelial ovarian cancer with non-disseminated lesions |
GO17-GO20 (11:40~12:20) |
ÁÂÀå : À̼±°æ(°æÈñÀÇ´ë) |
GO1711:40~11:50 |
ÀÌÁöÀ± ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Makorin Ring Finger Protein 1 (MKRN1) as an adjunct marker in liquid-based cervical cytology |
GO1811:50~12:00 |
ÀÌÁö¼± ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Predicting model for lymph node metastasis using preoperative tumor grade, transvaginal
ultrasound, and serum CA-125 level in patients with endometrial cancer |
GO1912:00~12:10 |
·ù±âÁø °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Clinical Significance of HPV DNA Co-testing in Korean Women with atypical squamous
cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H). |
GO2012:10~12:20 |
ÀÌÁö¿µ Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Cytokeratin 19 and human papilloma virus in lymph node of cervical cancer patients with intermediate risk factors |
GO21-GO24 (12:20~13:00) |
ÁÂÀå : À̱âÇå(°üµ¿ÀÇ´ë) |
GO2112:20~12:30 |
½Å¼ÒÁø °è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú |
The Hsp90 Inhibitor SY-016, Induces G2/M Arrest and Apoptosis in Paclitaxel-resistant Human Ovarian Cancer Cells |
GO2212:30~12:40 |
ÀÌ¹Î¾Æ ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú |
Synergistic effect of HPV E6/E7 siRNA in combination with Cisplatin on Basal dynamic
studies of TP53 |
GO2312:40~12:50 |
¼Õ±Ý¼± ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Chemosensitivity testing based on gene expression profiling in patients with ovarian cancer |
GO2412:50~13:00 |
±èÇüÁÖ ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Forkhead box P1 (Foxp1) in cervical cancer |
GO25-GO28 (14:00~14:40) |
ÁÂÀå : °í¼®ºÀ(´ë±¸°¡Å縯ÀÇ´ë) |
GO2514:00~14:10 |
±èÁ¤Áø ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
Comparison of barbed suture versus traditional suture in laparoendoscopic single-site myomectomy |
GO2614:10~14:20 |
¼ÕÁÖÇõ ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Cutoff value of pre- and post-cone HR-HPV load predicting residual/recurrent disease
after conization in high-grade intraepithelial neoplasia and microinvasive carcinoma of the
uterine cervix |
GO2714:20~14:30 |
À̽ÂÁ¤ °æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Single-port nerve sparing laparoscopic radical hysterectomy with extended node dissection for cervical cancer |
GO2814:30~14:40 |
¹èÀ縸 ÇѾç´ëÇб³º´¿ø »êºÎÀΰú |
Laparoscopic Cytoreductive Surgery in Women with Epithelial Ovarian Cancer |
GO29-GO33 (14:40~15:30) |
ÁÂÀå : ÇѼ¼ÁØ(Á¶¼±ÀÇ´ë) |
GO2914:40~14:50 |
±èÁöÈñ ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Detecting asymptomatic recurrence in early stage endometrial cancer- the value of vaginal cytology, imaging studies and CA-125 |
GO3014:50~15:00 |
±è¿¬¼± °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
Clinical impact of the number of the retrieved pelvic lymph nodes in epithelial ovarian cancer |
GO3115:00~15:10 |
±èÈñÁ¤ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Steroid Receptor Activator induces tumor proliferation and invasion through the Notch pathway in the human ovarian cancer |
GO3215:10~15:20 |
¼µ¿¼ö ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers
|
GO3315:20~15:30 |
ÀÌ´Ù¿ë ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Prognosis and Associated Factors in Neuroendocrine Cervical Carcinoma (NECC) |